^
    Back
    Association details:
    Biomarker:CCR4 positive
    Cancer:Leukemia
    Drug:Poteligeo (mogamulizumab-kpkc) (CCR4 receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

    Excerpt:
    ...Histologically confirmed diagnosis of a CCR4-positive ATL and...
    Trial ID:
    NCT00355472
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    A PHASE 2 TRIAL OF CHOP WITH ANTI-CCR4 ANTIBODY MOGAMULIZUMAB FOR ELDERLY PATIENTS WITH CCR4-POSITIVE ADULT T-CELL LEUKEMIA/LYMPHOMA

    Published date:
    06/09/2023
    Excerpt:
    This study demonstrated that Moga-CHOP-14 significantly improved PFS in elderly patients with aggressive CCR4-positive ATL who were ineligible for allo-HSCT.
    Secondary therapy:
    CHOP
    DOI:
    10.1002/hon.3163_125
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for elderly patients with CCR4-positive adult T-cell leukemia/lymphoma.

    Published date:
    05/25/2023
    Excerpt:
    CR and ORR were noted in 64.6% (95%CI, 49.5-77.8), and 91.7% (95% CI, 80.0-97.7), respectively. One-year OS was 66.0% (95% CI, 50.6-77.6) and median OS was 1.6 years (95%CI, 1.1-2.8). One-year EFS was 29.9% (95% CI, 17.6-43.2) and median EFS was 0.5 years (95%CI, 0.4-0.7)....This study demonstrated that Moga-CHOP-14 significantly improved PFS in elderly patients with aggressive CCR4-positive ATL who were ineligible for allo-HSCT.
    DOI:
    10.1200/JCO.2023.41.16_suppl.7504